Novavax to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights on November 4, 2021
Novavax, Inc. (Nasdaq: NVAX) announces it will report its third quarter 2021 financial results on November 4, 2021, post-market close. The company will host a conference call at 4:30 p.m. EDT to discuss its operational highlights. Participants are encouraged to join early for a timely connection. A replay will be available from 7:30 p.m. EDT on the same day until November 11, 2021. Novavax focuses on developing innovative vaccines to combat serious infectious diseases, including COVID-19 and influenza.
- Novavax is conducting late-stage clinical trials for its COVID-19 vaccine NVX-CoV2373.
- The NanoFlu™ vaccine candidate successfully met all primary objectives in its Phase 3 trial.
- None.
GAITHERSBURG, Md., Oct. 18, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its third quarter 2021 financial results and operational highlights on Thursday, November 4, 2021, following the close of U.S. financial markets. Details of the event and replay are as follows:
Conference call details: | |
Date: | November 4, 2021 |
Time: | 4:30 p.m. U.S. Eastern Daylight Time (EDT) |
Dial-in number: | (877) 870-426 (Domestic) or (412) 317-0790 (International) |
Webcast: |
- Participants will be prompted to request to join the Novavax, Inc. call.
- To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.
Replay details: | |
Date: | Available starting at 7:30 p.m. EDT, November 4, 2021 until 11:59 p.m. U.S. Standard Time, November 11, 2021 |
Dial-in number: | (877) 344-7529 (Domestic) or (412) 317-0088 (International) |
Passcode: | 10161242 |
Webcast: | www.novavax.com/events, until February 4, 2022 |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARSCoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Contacts:
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com
Solebury Trout
Alexandra Roy | 617-221-9197
aroy@soleburytrout.com
Media
Alison Chartan | 240-720-7804
Laura Keenan | 202-709-7521
media@novavax.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-third-quarter-financial-results-and-operational-highlights-on-november-4-2021-301402234.html
SOURCE Novavax, Inc.
FAQ
What date will Novavax report its Q3 2021 financial results?
What time is the Novavax Q3 financial results conference call?
How can I access the replay of Novavax's Q3 financial results call?
What is Novavax focusing on developing?
